Drona Smith News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Family members recently honored Joe Campos Torres, a Mexican American veteran killed by Houston Police Department officers in 1977.

UNION therapeutics’ COVID-19 candidates show promising results in phase 1 study Apr 7 2021 UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health – Europe (LINK). With no serious adverse effects reported, the study showed a strong safety profile of inhaled and intranasal niclosamide which was the primary endpoint for the trial. The promising safety and pharmacokinetic results for inhaled and intranasal niclosamide have opened the doors for further investigation, and...

UNION therapeutics' COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication The Lancet Regional Health - Europe has published the results of UNION therapeutics' phase 1 study of inhaled and intranasal niclosamide products (UNI91103 and UNI91104) The study endpoints were to assess the safety profile and the pharmacokinetic profile of niclosamide when administered as a nasal spray and as an inhalation product (nebulizer) The study was placebo-controlled and conducted in healthy volunteers No adverse effects were identified, paving the way for further investigation in COVID-...

UNI91103,developed by UNION therapeutics A/S,selected as first agent for prophylactic COVID-19 “PROTECT-V” study in high-risk patients UNI91103 is a nasal spray delivering niclosamide - a potent inhibitor of SARS-CoV-2 with in-vitro potency >40x higher than remdesivir - to the nasal cavityUNI9110...

He added: “I’m aware I am lucky. “I am retired, living in a house with a lovely big garden in a remote location, so in lockdown I could garden, walk the dogs, run around the garden to keep fit. “I don’t have the financial pressures of a younger man with small children, concerned not just for health but also finances. “I am also aware that if I was a high-shielder living in a city, I would not have been so relaxed.” Niclosamide is usually taken in tablet form to treat intestinal worms. For the clinical trial, it will be re-formulated into a nasal spray.